Alterity Therapeutics Ltd - Asset Resilience Ratio
Alterity Therapeutics Ltd (ATHE) has an Asset Resilience Ratio of 16.30% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ATHE total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Alterity Therapeutics Ltd's Asset Resilience Ratio has changed over time. See Alterity Therapeutics Ltd net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Alterity Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Alterity Therapeutics Ltd worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.50 Million | 16.3% |
| Total Liquid Assets | $7.50 Million | 16.30% |
Asset Resilience Insights
- Good Liquidity Position: Alterity Therapeutics Ltd maintains a healthy 16.30% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Alterity Therapeutics Ltd Industry Peers by Asset Resilience Ratio
Compare Alterity Therapeutics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Alterity Therapeutics Ltd (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Alterity Therapeutics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 16.30% | $7.50 Million | $46.03 Million | -- |
| 2024-06-30 | 0.00% | $0.00 | $19.22 Million | -- |
| 2019-06-30 | 0.00% | $0.00 | $19.91 Million | -- |
| 2018-06-30 | 0.05% | $9.51K | $18.73 Million | -0.12pp |
| 2017-06-30 | 0.17% | $43.99K | $25.28 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $33.73 Million | -- |
| 2015-06-30 | 0.36% | $152.60K | $41.83 Million | +0.39pp |
| 2013-06-30 | -0.02% | $-3.72K | $17.07 Million | -0.61pp |
| 2007-06-30 | 0.59% | $45.63K | $7.72 Million | +0.18pp |
| 2006-06-30 | 0.41% | $42.40K | $10.43 Million | -- |
About Alterity Therapeutics Ltd
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more